Plain-English translation of NCT06093438 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new approach for people with advanced cervical cancer that has a high risk of spreading. Researchers are adding a medication called —an immunotherapy drug that helps your immune system fight cancer—to standard chemotherapy before patients receive radiation treatment. The goal is to see whether this combination can reduce the chance that cancer will come back or spread to other parts of the body.
In advanced cervical cancer, cancer cells can spread to distant parts of the body even after standard treatment. Researchers believe that this medication, which works by waking up the immune system, might help prevent that spread when combined with chemotherapy before radiation therapy.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you would first receive the new immunotherapy medication combined with chemotherapy before your standard radiation treatment begins. This treatment phase prepares your body and immune system to fight the cancer. After you complete this induction phase, you would then receive the standard chemoradiation therapy that patients with your stage of cancer typically receive. Throughout the trial, you would have regular appointments for blood tests, imaging scans, and check-ups to monitor how you're responding to treatment.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Enrollment target
~20 participants
Started
November 2023
Primary completion
November 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Sex
Female only
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yuanjie Cao
Tianjin Medical University Cancer Institute and Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.